RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Frequently asked questions
What sector does RenovoRx Inc (RNXT) operate in?
RenovoRx Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is RenovoRx Inc (RNXT) current stock price?
As of the latest data, RenovoRx Inc stock price is $1.31, with a previous close of $1.29. RenovoRx Inc gained $0.02 in the last trading session, representing a 1.55% increase.
What is RenovoRx Inc (RNXT) current market capitalization?
RenovoRx Inc market cap is approximately 59.12 million.
What is RenovoRx Inc (RNXT) Earnings Per Share (EPS)?
The trailing EPS is -$0.31, and the forward EPS is -$0.12.
What is RenovoRx Inc (RNXT) EBITDA?
RenovoRx Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.91 million.
Does RenovoRx Inc (RNXT) pay dividends?
No. RenovoRx Inc does not pay a dividend.
How did RenovoRx Inc (RNXT) perform in its most recent earnings report?
In the last report (June 30, 2026), RenovoRx Inc posted an EPS surprise of 37.5% and a revenue surprise of 29.17%.
What is RenovoRx Inc (RNXT) beta (volatility) score?
RenovoRx Inc has a beta of 1.121, meaning its volatility is roughly in line with the market.